

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 16 MAY 2024**

Reference is made to the circular (“**Circular**”) and the notice (“**Notice**”) of annual general meeting (“**AGM**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) both dated 22 April 2024. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

### **ANNUAL GENERAL MEETING**

At the AGM held on 16 May 2024 all the proposed resolutions as set out in the Notice were taken by poll.

As at the date of the AGM, the total number of issued shares of the Company (the “**Shares**”) was 2,032,890,585 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There was no restriction on any shareholders of the Company (the “**Shareholder(s)**”) casting votes on any of the proposed resolutions at the AGM. No Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the AGM and no Shareholders were entitled to attend and abstain from voting in favour as set out in rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM. All directors of the Company attended the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended 31 December 2023 and the reports of the directors and independent auditor thereon.	1,089,804,000 (100.000000%)	0 (0.000000%)
2.	(a) To re-elect the following directors of the Company (the “ <b>Directors</b> ”):		
	(i) Mr. Huang Zhijian as an executive Director;	1,089,804,000 (100.000000%)	0 (0.000000%)
	(ii) Mr. Wang Qing as an independent non-executive Director; and	1,089,804,000 (100.000000%)	0 (0.000000%)
	(iii) Mr. Bai Zhizhong as an independent non-executive Director;	1,089,804,000 (100.000000%)	0 (0.000000%)
(b)	To authorise the board of directors of the Company (the “ <b>Board</b> ”) to fix the remuneration of the Directors.	1,089,804,000 (100.000000%)	0 (0.000000%)
3.	To re-appoint CL Partners CPA Limited as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorize the Board to fix their remuneration for the year ending 31 December 2024.	1,089,804,000 (100.000000%)	0 (0.000000%)
4.	To approve the recommended final dividend of HK0.39 cents per ordinary share in an aggregate amount of HK\$8,000,000 for the year ended 31 December 2023.	1,089,804,000 (100.000000%)	0 (0.000000%)
5.	(A) To grant a general mandate to the directors to allot, issue and deal with additional shares not exceeding 20% of the number of issued shares of the Company.	1,089,756,000 (99.995596%)	48,000 (0.004404%)
	(B) To grant a general mandate to the directors to repurchase shares not exceeding 10% of the number of issued shares of the Company.	1,089,804,000 (100.000000%)	0 (0.000000%)
	(C) Conditional upon the passing of ordinary resolutions numbered 5(A) and 5(B), to extend the authority granted to directors pursuant to ordinary resolution numbered 5(A) to issue shares by adding number of issued shares of the Company which may be allotted by the directors of the Company pursuant to such general mandate of an amount representing the number of shares repurchased under ordinary resolution numbered 5(B).	1,089,756,000 (99.995596%)	48,000 (0.004404%)

Note: Please refer to the Notice for the full text of the resolutions.

As more than 50% of votes were cast in favour of each of the resolutions 1 to 5, all the above ordinary resolutions were duly passed at the AGM.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 16 May 2024

*As at the date of this announcement, the executive Director are Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.*